Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.71 |
| ▸ | KDR | P35968 | 12/20 | 0.68 |
| ▸ | SRC | P12931 | 5/20 | 0.68 |
| ▸ | BRAF | P15056 | 4/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | MET | P08581 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | LTK | P29376 | 2/20 | 0.68 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.68 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.68 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468777 | 0.92 | ERBB2 (0.67) | EGFRKDRSRCBRAFEPHB4 | |
| SCHEMBL4461895 | 0.88 | EGFR (0.73) | EGFRKDREPHB4ERBB2EPHA2 | |
| SCHEMBL4466847 | 0.88 | ERBB2 (0.58) | EGFRKDRSRCBRAFEPHB4 | |
| SCHEMBL4466222 | 0.86 | ERBB2 (0.69) | EGFRERBB2 | |
| SCHEMBL4464007 | 0.86 | ERBB2 (0.70) | EGFRSRCABL1ERBB2FYN | |
| SCHEMBL4461439 | 0.85 | ERBB2 (0.74) | EGFRKDRSRCBRAFEPHB4 | |
| SCHEMBL4416773 | 0.84 | EGFR (0.71) | EGFRKDRSRCBRAFEPHB4 | |
| Gefitinib SCHEMBL17241499 | 0.83 | EGFR (0.87) | EGFRKDRSRCBRAFEPHB4 | |
| SCHEMBL12536465 | 0.83 | EGFR (0.70) | EGFRKDRSRCBRAFEPHB4 | |
| SCHEMBL15591842 | 0.83 | EGFR (0.89) | EGFRKDRSRCBRAFEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | claimed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | EGFR 166/4885KDR 1855/4885SRC 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.